

Emmanuelle Voisin, Ph.D.
Principal

Dr. Emmanuelle Voisin Lestringant founded Voisin Consulting in 1997. The company has become a leading product development consulting firm, advising start-up companies developing innovative healthcare products. Her expertise includes designing development plans including preclinical and clinical programs, and identifying regulatory strategies to bring the products to the market in a fast and efficient manner.

Dr. Emmanuelle Voisin has more than 20 years of experience in nonclinical development of medicinal products. Her expertise in regulatory toxicology ranges from the design of the programs, to supervision, monitoring and reporting of studies, as well as writing of the nonclinical sections of regulatory documents. Her interest is also in the extrapolation of animal data to humans and the design of the first in man clinical trials.

Previously, Dr. Emmanuelle Voisin was General Manager of Quintiles France and Spain. She started the Quintiles operations in Southern European countries, including France, Italy, Spain and Portugal. She also conducted clinical trials in Eastern European countries, mainly Poland and Czech Republic. She participated in due diligences and negotiations for acquisitions in France and the UK. Dr. Voisin started and headed the European Regulatory Affairs Strategic Business Unit for all Quintiles geographic locations across Europe.

Dr. Voisin held a position as Reviewing Pharmacologist and Toxicologist with the US FDA CDER Division of Antiviral Drug Products, where she was in charge of reviewing applications for new AIDS therapies. She gained pharmaceutical industry experience in preclinical and clinical drug development, both from Laboratoires Servier in France and Laboratoires Besins Iscovesco-International- in the USA.

Her background in academic research was acquired in the USA at the National Institute of Mental Health, NIMH in the Neuroscience Branch, and in France with national research units, CNRS and INSERM at Institut Gustave Roussy. Dr. Voisin obtained her Ph.D. in Pharmacology at Institut Gustave Roussy, Villejuif, France, studying the bioactivation of novel anticancer molecules. Dr. Voisin is a member of Regulatory Affairs Professionals Society (RAPS) and Drug Information Association (DIA).